Histide AG, a Swiss biotech company founded in 2014, has raised CHF 4.5 million (€3.74 million) to develop its extracellular technology for directing cell fate. The funds were provided by Parter Capital Group AG and a number of private investors. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals